This CPB has been revised to add the following medical necessity criteria for infliximab therapy: (i) for initial approval, added requirement that member be tested for biomarkers Rheumatoid Factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) and the test was positive [or tested for RF, anti-CCP, and c-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)] if the member has no prior biologic or targeted synthetic DMARD use in rheumatoid arthritis (RA), and (ii) for continuation of therapy: added specific continuation criteria for Crohn’s disease, ulcerative colitis, RA, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, juvenile idiopathic arthritis, uveitis, and reactive arthritis. This CPB has been updated with the following: (i) for Aetna commercial plans, change "Least Cost Medically Necessary Brands" subheading to "Brand Selection for Medically Necessary Indications", (ii) update nomenclature for "Brand Selection for Medically Necessary Indications" to reflect Aetna commercial plan language, (iii) updated the TB nomenclature, (iv) updated the table in the appendix for brands of targeted immune modulators and FDA-approved indications, and (v) added and reorganized subheaders.